183 related articles for article (PubMed ID: 37935260)
21. The Spectrum of Inborn Errors of Immunity in the United Arab Emirates: 5 Year Experience in a Tertiary Center.
Shendi HM; Al Kuwaiti AA; Al Dhaheri AD; Al-Hammadi S
Front Immunol; 2022; 13():837243. PubMed ID: 35173743
[TBL] [Abstract][Full Text] [Related]
22. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
23. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Loscocco GG; Vannucchi AM
Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
[TBL] [Abstract][Full Text] [Related]
24. Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders.
Consonni F; Dotta L; Todaro F; Vairo D; Badolato R
Curr Opin Pediatr; 2017 Dec; 29(6):711-717. PubMed ID: 28914637
[TBL] [Abstract][Full Text] [Related]
25. Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis.
Bloomfield M; Zentsova I; Milota T; Sediva A; Parackova Z
Front Immunol; 2022; 13():983977. PubMed ID: 36172362
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
27. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
28. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Bechman K; Yates M; Galloway JB
Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
[TBL] [Abstract][Full Text] [Related]
29. Primary Immune Deficiency Treatment Consortium (PIDTC) report.
Griffith LM; Cowan MJ; Notarangelo LD; Kohn DB; Puck JM; Pai SY; Ballard B; Bauer SC; Bleesing JJ; Boyle M; Brower A; Buckley RH; van der Burg M; Burroughs LM; Candotti F; Cant AJ; Chatila T; Cunningham-Rundles C; Dinauer MC; Dvorak CC; Filipovich AH; Fleisher TA; Bobby Gaspar H; Gungor T; Haddad E; Hovermale E; Huang F; Hurley A; Hurley M; Iyengar S; Kang EM; Logan BR; Long-Boyle JR; Malech HL; McGhee SA; Modell F; Modell V; Ochs HD; O'Reilly RJ; Parkman R; Rawlings DJ; Routes JM; Shearer WT; Small TN; Smith H; Sullivan KE; Szabolcs P; Thrasher A; Torgerson TR; Veys P; Weinberg K; Zuniga-Pflucker JC;
J Allergy Clin Immunol; 2014 Feb; 133(2):335-47. PubMed ID: 24139498
[TBL] [Abstract][Full Text] [Related]
30. Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.
Hadjadj J; Frémond ML; Neven B
Front Immunol; 2021; 12():717388. PubMed ID: 34603291
[TBL] [Abstract][Full Text] [Related]
31. Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity.
Del Rosal T; Quintana-Ortega C; Deyá-Martinez A; Soler-Palacín P; Goycochea-Valdivia WA; Salmón N; Pérez-Martínez A; Alsina L; Martín-Nalda A; Alonso L; Neth O; Bravo-Gallego LY; Gonzalez-Granado LI; Mendez-Echevarria A
Eur J Pediatr; 2022 Nov; 181(11):3889-3898. PubMed ID: 36102997
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1.
Lévy R; Escudier A; Bastard P; Briand C; Polivka L; Stoupa A; Talbotec C; Rothenbuhler A; Charbit M; Debray D; Bodemer C; Casanova JL; Linglart A; Neven B
J Clin Immunol; 2023 Dec; 44(1):5. PubMed ID: 38112858
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG; Charbonnier LM; Alroqi F; Plant A; Qiao Q; Wu H; Ma C; Torgerson TR; Rosenzweig SD; Fleisher TA; Notarangelo LD; Hanson IC; Forbes LR; Chatila TA
J Allergy Clin Immunol; 2017 May; 139(5):1629-1640.e2. PubMed ID: 28139313
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic Hematopoietic Stem Cell Transplantation Activity in Inborn Errors of Immunity in Russian Federation.
Laberko A; Mukhinа A; Machneva E; Pashchenko O; Bykova T; Vahonina L; Bronin G; Skvortsova Y; Skorobogatova E; Kondratenko I; Fechina L; Shcherbina A; Zubarovskaya L; Balashov D; Rumiantsev A
J Clin Immunol; 2023 Aug; 43(6):1241-1249. PubMed ID: 37009957
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Genetic Spectrum of Inborn Errors of Immunity in a Tertiary Care Center in Southern India.
Lashkari HP; Madkaikar M; Dalvi A; Gupta M; Bustamante J; Sharma M; Rawat A; Bhatia P; Bhat KG; Rao S; Kamath N; Moideen F; Latour S; Winter S; Bhavani GS; Girisha KM
Indian J Pediatr; 2022 Mar; 89(3):233-242. PubMed ID: 34826056
[TBL] [Abstract][Full Text] [Related]
36. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.
Baris S; Alroqi F; Kiykim A; Karakoc-Aydiner E; Ogulur I; Ozen A; Charbonnier LM; Bakır M; Boztug K; Chatila TA; Barlan IB
J Clin Immunol; 2016 Oct; 36(7):641-8. PubMed ID: 27379765
[TBL] [Abstract][Full Text] [Related]
37. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors in systemic juvenile idiopathic arthritis.
He T; Xia Y; Luo Y; Yang J
Front Pediatr; 2023; 11():1134312. PubMed ID: 37152309
[TBL] [Abstract][Full Text] [Related]
39. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
